171 related articles for article (PubMed ID: 22652109)
21. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
[TBL] [Abstract][Full Text] [Related]
22. Conformal postoperative radiotherapy in patients with positive resection margins and/or pT3-4 prostate adenocarcinoma.
Bellavita R; Massetti M; Abraha I; Lupattelli M; Mearini L; Falcinelli L; Farneti A; Palumbo I; Porena M; Aristei C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e299-304. PubMed ID: 22572075
[TBL] [Abstract][Full Text] [Related]
23. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
[TBL] [Abstract][Full Text] [Related]
24. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
Hanlon AL; Diratzouian H; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
[TBL] [Abstract][Full Text] [Related]
25. High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal Therapy.
Son CH; Hamstra DA; Feng FY; Liauw SL
Am J Clin Oncol; 2017 Aug; 40(4):348-352. PubMed ID: 25436827
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
27. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
28. Prolongation of total treatment time because of infrequently missed days of treatment is not associated with inferior biochemical outcome after dose-escalated radiation therapy for prostate cancer.
Liauw SL; Liauw SH
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):751-7. PubMed ID: 20932666
[TBL] [Abstract][Full Text] [Related]
29. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
Zagars GK; Pollack A; Smith LG
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
[TBL] [Abstract][Full Text] [Related]
30. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
Ko EC; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
[TBL] [Abstract][Full Text] [Related]
31. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
Pollack A; Smith LG; von Eschenbach AC
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):507-12. PubMed ID: 10974469
[TBL] [Abstract][Full Text] [Related]
32. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
Nguyen KH; Horwitz EM; Hanlon AL; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):377-83. PubMed ID: 12957248
[TBL] [Abstract][Full Text] [Related]
33. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
[TBL] [Abstract][Full Text] [Related]
34. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
[TBL] [Abstract][Full Text] [Related]
35. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer.
Kupelian PA; Ciezki J; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):16-22. PubMed ID: 17996382
[TBL] [Abstract][Full Text] [Related]
36. Postneoadjuvant hormone PSA levels and prognosis in locally advanced prostate cancer.
Velasco J; Tekyi-Mensah S; Bolton S; Forman JD
Urology; 1999 Aug; 54(2):325-8. PubMed ID: 10443733
[TBL] [Abstract][Full Text] [Related]
37. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
[TBL] [Abstract][Full Text] [Related]
38. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.
Thames H; Kuban D; Levy L; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):929-43. PubMed ID: 14575823
[TBL] [Abstract][Full Text] [Related]
39. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
[TBL] [Abstract][Full Text] [Related]
40. Salvage radiotherapy for prostate cancer recurrence after cryosurgical ablation.
Burton S; Brown DM; Colonias A; Cohen J; Miller R; Rooker G; Benoit R; Merlotti L; Quinn A; Kalnicki S
Urology; 2000 Nov; 56(5):833-8. PubMed ID: 11068312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]